Director/PDMR Shareholding
GW Pharmaceuticals
735.00p
16:34 02/12/16
HOWDEN JOINERY GROUP PLC
(the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
The Company has been notified that Paul Hayes, the Chief Financial Officer and person discharging managerial responsibility ("PDMR"), purchased 7,000 ordinary shares in the Company through the London Stock Exchange at a price of 714.00 pence per share.
The Notification of Dealing Form for Mr Hayes may be found below. This notification is provided in accordance with the requirements of UK MAR.
Notification of dealing form
1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
a) | Name | Paul Hayes | |||
2 | Reason for the notification | ||||
a) | Position/status | Chief Financial Officer | |||
b) | Initial notification/ Amendment | Initial notification | |||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | Howden Joinery Group plc | |||
b) | LEI | 213800KC1LJOJTY3JP45 | |||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument |
Ordinary shares of 10 pence each
| |||
Identification code | GB0005576813 | ||||
b) | Nature of the transaction | Purchase of ordinary 10 pence shares | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
GBP 7.14 | 7,000 | ||||
d) | Aggregated information | Price(s) | Volume(s) | Aggregate Total | |
GBP 7.14 | 7,000 | GBP 49,980.00 | |||
e) | Date of the transaction | 2021-03-10 | |||
f) | Place of the transaction | London Stock Exchange (XLON) | |||
Enquiries
Forbes McNaughton, Company Secretary: +44(0)20 7535 1137
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.